Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
作者信息
Szucs Zoltan, Joseph James, Larkin Tim J, Xie Bangwen, Bohndiek Sarah E, Brindle Kevin M, Neves André A
机构信息
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.
Department of Physics, University of Cambridge, Cambridge, UK.
出版信息
Breast Cancer Res. 2021 Mar 15;23(1):32. doi: 10.1186/s13058-021-01414-x.
Abstract
摘要
相似文献
1
Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.对《使用C2Am：一种靶向细胞死亡成像剂对乳腺高危导管原位癌进行多模态成像》的更正
Breast Cancer Res. 2021 Mar 15;23(1):32. doi: 10.1186/s13058-021-01414-x.
2
Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.使用 C2Am 对乳腺高危导管原位癌进行多模态成像：一种靶向细胞死亡成像剂。
Breast Cancer Res. 2021 Feb 17;23(1):25. doi: 10.1186/s13058-021-01404-z.
3
F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography.F-C2Am：一种用于通过正电子发射断层扫描在体内检测肿瘤细胞死亡的靶向成像剂。
EJNMMI Res. 2020 Dec 9;10(1):151. doi: 10.1186/s13550-020-00738-7.
4
Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I.利用突触结合蛋白 I 的 C2A 结构域在体快速成像肿瘤细胞死亡。
J Nucl Med. 2017 Jun;58(6):881-887. doi: 10.2967/jnumed.116.183004. Epub 2017 Feb 16.
5
Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am.使用镓-68标记的C2Am对治疗后肿瘤细胞死亡进行的临床前正电子发射断层显像（PET）成像
Cancers (Basel). 2023 Mar 2;15(5):1564. doi: 10.3390/cancers15051564.
6
Optoacoustic Detection of Early Therapy-Induced Tumor Cell Death Using a Targeted Imaging Agent.利用靶向成像剂的光声检测早期治疗诱导的肿瘤细胞死亡。
Clin Cancer Res. 2017 Nov 15;23(22):6893-6903. doi: 10.1158/1078-0432.CCR-17-1029. Epub 2017 Aug 18.
7
Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report.男性乳腺高级别导管原位癌的磁共振成像表现：一例报告
SAGE Open Med Case Rep. 2018 Jun 12;6:2050313X18781727. doi: 10.1177/2050313X18781727. eCollection 2018.
8
Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study.1990 年至 2018 年英格兰非筛查检出导管原位癌后的浸润性乳腺癌和乳腺癌死亡：基于人群的队列研究。
BMJ. 2024 Jan 24;384:e075498. doi: 10.1136/bmj-2023-075498.
9
Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.导管原位癌的治疗：利弊平衡尚不确定。
Prescrire Int. 2013 Dec;22(144):298-303.
10
Ductal Carcinoma In situ of the Male Breast.男性乳腺导管原位癌
Breast Care (Basel). 2016 Aug;11(4):288-290. doi: 10.1159/000447768. Epub 2016 Aug 5.
引用本文的文献
1
Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.使用与白蛋白结合域偶联的IRDye800CW-DOTA改进多模态肿瘤坏死成像。
Cancers (Basel). 2022 Feb 9;14(4):861. doi: 10.3390/cancers14040861.
本文引用的文献
1
Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.使用 C2Am 对乳腺高危导管原位癌进行多模态成像：一种靶向细胞死亡成像剂。
Breast Cancer Res. 2021 Feb 17;23(1):25. doi: 10.1186/s13058-021-01404-z.
Zotero 插件